Usana Health Sciences, Inc. · NYSE:USNA
Usana Health Sciences — Q1 2026 Earnings Presentation
10 slides from Usana Health Sciences's earnings presentation, May 6, 2026
Slide 1: USANA Health Sciences Reports First Quarter 2026 Results
May 5, 2026 USANA Health Sciences Reports First Quarter 2026 Results Company Continues to Make Significant Progress on Transformation to Becoming a Leading Omnichannel Health and Wellness Platform SALT LAKE CITY--(BUSINESS WIRE)-- USANA Health Sciences, Inc. (NYSE: USNA) today announced financial re
Slide 2: Q1 2026 Segment Results
“As we look ahead, the investments we are making today in product innovation, brand building, channel expansion, and technology modernization reinforce confidence in our strategic direction. These investments position us to compete effectively across the full spectrum of health-conscious consumer sh
Slide 3: Fiscal Year 2026 Outlook
$8 million, or -7% compared to balances at year-end 2025. This decrease was driven by strong performance by Rise Wellness, particularly from the fulfillment of orders with key retailers. The Company did not repurchase any shares during the quarter and has approximately $34 million remaining under th
Slide 4: Adjusted Diluted EPS and Adjusted EBITDA
as indicated below in the reconciliation from net earnings. Adjusted diluted EPS is a non- GAAP financial measure of diluted earnings per share that excludes certain adjustments as indicated below in the reconciliation from diluted EPS. Adjusted EBITDA (non-GAAP) is net earnings (its most directly c
Slide 5: Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (non-GAAP)
Reconciliation of Net Earnings (GAAP) to Adjusted EBITDA (non-GAAP) (in thousands) Quarter ended April 4, March 29, 2026 2025 Net earnings attributable to USANA (GAAP) $ 7,515 $ 9,402 Net (loss) earnings attributable to noncontrolling interest (556) (112) Net earnings $ 6,959 $ 9,290 Adjustments: In
Slide 6: Safe Harbor
Safe Harbor This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. These forward-looking statements are based on current plans, expectations, estimates, forecasts, and projections as well as the b
Slide 7: Risk Factors and Forward-Looking Statements
risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission. The forward-looking statements in this press release set forth our beliefs as of the date hereof. We do not undertake any obligation to update any forward-look
Slide 8: Condensed Consolidated Balance Sheets
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) As of As of April 4, January 3, 2026 2026 ASSETS Current assets Cash and cash equivalents $ 162,751 $ 158,380 Trade accounts receivable (net of allowance of $141 and $137, respectively) 9,65
Slide 9: Sales by Region
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES SALES BY REGION (in thousands) (unaudited) Quarter ended Percent Change change from Currency excluding April 4, March 29, prior Percent impact on currency 2026 2025 year change sales impact Core Nutritional: Asia Pacific Greater China $ 123,334 49.3% $ 11
Slide 10: Operating Results as a Percentage of Net Sales
USANA HEALTH SCIENCES, INC. AND SUBSIDIARIES OPERATING RESULTS AS A PERCENTAGE OF NET SALES (unaudited) Quarter ended April 4, 2026 March 29, 2025 Core Core Nutritional Hiya Rise Consolidated Nutritional Hiya Rise Consolidated Net sales 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% Cost of
USANA Health Sciences — Q1 2026 Earnings Presentation on 6ix